Synergistic properties between a MEK inhibition and fluoropyrimidine have also been reported for other cancer types.23–25 Interestingly, in this study, all patients who had previously failed fluoropyrimidine-based chemotherapy achieved either a PR or SD with this combination, which is likely attributed to synergism. This evidence concerns the gene MAP2K7 and cancer.